行情

CANF

CANF

灿菲特生物制药
AMEX

实时行情|Nasdaq Last Sale

1.740
0.000
0.00%
休市 16:00 09/17 EDT
开盘
1.730
昨收
1.740
最高
1.750
最低
1.710
成交量
5.70万
成交额
--
52周最高
4.390
52周最低
1.640
市值
3,321.93万
市盈率(TTM)
-2.4576
分时
5日
1月
3月
1年
5年
Can-Fite 将参加即将举行的三场制药合作会议
PETACH TIKVA, Israel, September 17, 2021--Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
Business Wire · 20小时前
Can-Fite 将出席 HC Wainwright 第 23 届年度全球投资大会
PETACH TIKVA, Israel, September 09, 2021--Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Business Wire · 09/09 11:00
Brief-Can-Fite 在第三阶段银屑病研究中完成患者登记
reuters.com · 09/02 11:36
Can-Fite 报告已完成第 3 期银屑病研究的患者登记;预计 22 年第一季度的顶线结果
Positive interim analysis data was released in October 2020 based on results from 200 patients Topline results expected Q1 2022 PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE:CANF)
Benzinga · 09/02 11:04
Can-Fite 完成 III 期银屑病研究的患者登记
PETACH TIKVA, Israel, September 02, 2021--Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
Business Wire · 09/02 11:00
Can-Fite 报告 2021 年上半年收入下降,净亏损同比下降 38%
Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.
Benzinga · 08/26 16:48
Can-Fite 报告 2021 年第二季度财务业绩并提供临床更新
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June ...
Business Wire · 08/26 11:00
HVBT、PSTI 和 DPW 是上市前的赢家
Enlivex Therapeutics ENLV +22% to launch Phase IIb Allocetra trial for COVID-19 patients in Israel ADMA Biologics ADMA +17% on FDA approval for plasma collection facility in Maryville, TN Travere Therapeutics TVTX +17% meets primary efficacy
Seekingalpha · 08/16 12:42
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CANF最新的财务预测,通过CANF每股收益,每股净资产,每股现金流等数据分析灿菲特生物制药近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CANF价格均价为6.00,最高价位9.00,最低价为5.00。
EPS
机构持股
总机构数: 9
机构持股: 35.60万
持股比例: 1.86%
总股本: 1,909.15万
类型机构数股数
增持
1
3.37万
建仓
3
22.49万
减持
4
5
平仓
1
913
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.40%
制药与医学研究
-0.10%
高管信息
Chairman/Director
Ilan Cohen
Chief Executive Officer/Director
Pnina Fishman
Chief Financial Officer/Chief Operating Officer
Motti Farbstein
Director
Guy Regev
Director
Abraham Sartani
Director
Israel Shamay
暂无数据
CANF 简况
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

微牛提供Can Fite Biopharma Ltd(AMEX-CANF)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CANF股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CANF股票基本功能。